PF-Atlas › Клинические испытания › NCT01079091
Hepa Wash Treatment of Patients With Acute-on-Chronic Liver Failure in Intensive Care Units
ADVOS · Не указано
ID реестра
NCT01079091
Фаза
Не указано
Статус
Прекращено
Препарат / вмешательство
ADVOS (Hepa Wash)
Спонсор
Hepa Wash GmbH
Начало
2010-09
Набор участников
14
Центры
1
Об исследовании
Patients with compensated chronic liver disease who have an episode of acute deterioration of liver function (acute-on-chronic liver failure) are known to have up to 90% mortality rate. Hepa Wash(R) is a newly developed liver and renal support system that is based on the use of recycled albumin dialysate. The new system has shown a high detoxification capacity in in-vitro and preclinical studies. The aim of the study is to evaluate the safety and efficacy of the Hepa Wash system in patients with acute-on-chronic liver failure in the intensive care unit.
Связанные материалы
Медицинская оговорка. Эта страница обобщает публичные данные исследования NCT01079091 только для информации. Это не медицинская рекомендация, не одобрение и не предложение участия. Проверяйте детали на ClinicalTrials.gov и у квалифицированного врача.